74733-26-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-chloro-4-formylbenzoate is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex organic molecules that can have therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 3-chloro-4-formylbenzoate is utilized as an intermediate in the production of various agrochemicals, potentially aiding in the development of new pesticides or other agricultural products.
Used in Organic Synthesis Research:
Methyl 3-chloro-4-formylbenzoate serves as a valuable compound in organic synthesis research, where it can be used to explore new reaction pathways and develop novel organic compounds with potential applications in various fields.
It is important to handle Methyl 3-chloro-4-formylbenzoate with care, as it may pose health risks if not properly managed or used in a controlled environment.

Upstream product

• 74733-30-5 methyl 4-Bromomethyl-3-chlorobenzoate 
• 1571-08-0 methyl 4-formylbenzoate 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 158435-41-7 4-bromo-2-chlorobenzaldehyde 
• 56525-63-4 methyl 3-chloro-4-methyl-benzoate 
• 1134777-59-5 methyl 3-chloro-4-(dibromomethyl)benzoate 

Downstream Products

• 570407-86-2 C₁₂H₁₆ClNO₃ 
• 1173176-93-6 methyl 3-chloro-4-(oxazol-5-yl)benzoate 
• 1460036-67-2 2,5-dioxopyrrolidin-1-yl 4-{[2-chloro-4-(morpholine-4-carbonyl)phenyl]methyl}piperazine-1-carboxylate 
• 1460036-77-4 4-[[3-chloro-4-(piperazin-1-ylmethyl)phenyl]carbonyl]morpholine 
• 1460036-74-1 tert-butyl 4-([2-chloro-4-[(morpholin-4-yl)carbonyl]phenyl]methyl)piperazine-1-carboxylate 
• 1446819-30-2 4-([4-[(tert-butoxy)carbonyl]piperazin-1-yl]methyl)-3-chlorobenzoic acid 
• 1446819-29-9 tert-butyl 4-[[2-chloro-4-(methoxycarbonyl)phenyl]methyl]piperazine-1-carboxylate 
• 1350197-58-8 C₁₈H₁₀BrClN₂O₄ 

Relevant academic research and scientific papers

Diverse ortho-C(sp2)-H functionalization of benzaldehydes using transient directing groups

Pd-catalyzed C-H functionalizations promoted by transient directing groups remain largely limited to C-H arylation only. Herein, we report a diverse set of ortho-C(sp2)-H functionalizations of benzaldehyde substrates using the transient directing group strategy. Without installing any auxiliary directing group, Pd(II)-catalyzed C-H arylation, chlorination, bromination, and Ir(III)-catalyzed amidation, could be achieved on benzaldehyde substrates. The transient directing groups formed in situ via imine linkage can override other coordinating functional groups capable of directing C-H activation or catalyst poisoning, significantly expanding the scope for metal-catalyzed C-H functionalization of benzaldehydes. The utility of this approach is demonstrated through multiple applications, including late-stage diversification of a drug analogue.

PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF

The invention provides pyrrolo-pyrrole carbamate and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., solid tumor cancer, obesity, Down's syndrome, Alzheimer's disease, or pain, in a patient. The octahydropyrrolo pyrrole carbamates could be derived from hexafluoroisopropanol, Ν,Ν-disuccinimide and such. The activity of carbamates in MAGL, FAAH, and ABHD6 assays are also described.

NMDA RECEPTOR MODULATORS AND USES RELATED THERETO

This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiments, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof. In certain embodiments, the disclosure relates to methods of treating or preventing nervous system disorders comprising administering an effective amount of a composition comprising compound disclosed herein to a subject in need thereof.

Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators

NMDA receptors are tetrameric complexes composed of GluN1 and GluN2A-D subunits that mediate a slow Ca2+-permeable component of excitatory synaptic transmission. NMDA receptors have been implicated in a wide range of neurological diseases and thus represent an important therapeutic target. We herein describe a novel series of pyrrolidinones that selectively potentiate only NMDA receptors that contain the GluN2C subunit. The most active analogues tested were over 100-fold selective for recombinant GluN2C-containing receptors over GluN2A/B/D-containing NMDA receptors as well as AMPA and kainate receptors. This series represents the first class of allosteric potentiators that are selective for diheteromeric GluN2C-containing NMDA receptors.

Heterobiaryl human immunodeficiency virus entry inhibitors

Previously disclosed HIV (human immunodeficiency virus) attachment inhibitors, exemplified by BMS 806 (formally BMS378806, 1), are characterized by a substituted indole or azaindole ring linked to a benzoylpiperazine via a ketoamide or sulfonamide group. In the present report, we describe the discovery of a novel series of potent HIV entry inhibitors in which the indole or azaindole ring of previous inhibitors is replaced by a heterobiaryl group. Several of these analogues exhibited IC50 values of less than 5 nM in a pseudotyped antiviral assay, and compound 13k was demonstrated to exhibit potency and selectivity similar to those of 1 against a panel of clinical viral isolates. Moreover, current structure-activity relationship studies of these novel biaryl gp120 inhibitors revealed that around the biaryl, a fine crevice might exist in the gp120 binding site. Taken in sum, these data reveal a hitherto unsuspected flexibility in the structure-activity relationships for these inhibitors and suggest new avenues for exploration and gp120 inhibitor design. 2009 American Chemical Society.

SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS

Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.